Novavax (NVAX) Starts Developing Omicron-Specific COVID Jab

Published on December 3, 2021

Novavax (NVAX) begins evaluating its COVID-19 vaccine against the Omicron variant. The company also starts developing an Omicron-specific COVID-19 vaccine.

Continue reading on website
Other news

SL Green Realty (SLG) Hikes Dividend, Grants Special Dividend

December 3, 2021
To reward its shareholders, SL Green's (SLG) board of directors approves a 2.5% hike in its annual ordinary dividend and clears a special dividend too.

Dyne Therapeutics (DYN) Submits IND to FDA for DMD Candidate

December 3, 2021
Dyne Therapeutics (DYN) files an investigational new drug application in the United States for a clinical study on its investigational candidate DYNE-251 to address Duchenne Muscular Dystrophy.